Genetic mutations cause up to 15% of cases of Parkinson's disease. In this test-specific episode of the "Answers From the Lab" podcast, Zhiyv (Neal) Niu, Ph.D., and Rodolfo Savica, M.D., Ph.D., explain why Mayo Clinic Laboratories' gene panel outperforms other commercially available tests for inherited Parkinson's disease.

"Our test is the most comprehensive available in the market. It looks at 94 genes — more than three times the number analyzed in other commercially available tests," Dr. Savica says.

The novel panel identifies not only mutations known to cause Parkinson's disease but also mutations that increase the risk of developing it.

"This test can be incredibly helpful for patients who have a family history of Parkinson's disease and also patients with earlier onset of disease," Dr. Savica says. "We now have a bigger piece of the puzzle — something that can really allow an individualized approach towards Parkinson's disease."

Listen to learn more about Mayo Clinic Laboratories' inherited Parkinson's disease gene panel.

Note: Podcasts will not play back on Internet Explorer. Please use an alternative web browser, or listen from your mobile device on a preferred listening app.

Testing

PARDP  | Inherited Parkinson Disease Gene Panel, Varies

Useful information

• Establishing a molecular diagnosis for patients with Parkinson disease
• Identifying variants within genes known to be associated with Parkinson disease, allowing for predictive testing of at-risk family members

Specimen requirements

Patient Preparation:

A previous bone marrow transplant from an allogenic donor will interfere with testing. Call 800-533-1710 for instructions for testing patients who have received a bone marrow transplant.

Specimen Type: Whole blood

Container/Tube: Lavender top (EDTA) or yellow top (ACD)

Acceptable: Any anticoagulant

Specimen Volume: 3 mL

Collection Instructions:

1. Invert several times to mix blood.
2. Send whole blood specimen in original tube. Do not aliquot.

Specimen Stability Information: Ambient (preferred)/Refrigerated

Performance information

• Analytic time: 28 to 42 days
• Day(s) and time(s) performed: Varies

The latest

Unique Test Screens for Recently Identified Peripheral Neuropathy: Matthew Schultz, Ph.D., and Amy White, M.S., CGC

September 24, 2024

Matthew J. Schultz, Ph.D., and Amy L. White, M.S., CGC, explain how Mayo Clinic Laboratories' unique urine assay (Mayo ID: SORD) screens for peripheral neuropathy arising from SORD gene variants. Although recently identified, SORD-related peripheral neuropathy is fairly common.

Panel Detects Demyelinating Neuropathy Biomarkers: John Mills, Ph.D., and Divyanshu Dubey, M.B.B.S.

September 17, 2024

John Mills, Ph.D., and Divyanshu Dubey, M.B.B.S., explain how Mayo Clinic Laboratories' new test panel can distinguish among various potential causes of demyelinating neuropathies. Test results are important for managing these devastating autoimmune conditions.

Genetic Tests Identify Risk of Fluoropyrimidine-Induced Toxicity: Ann Moyer, M.D., Ph.D.

September 10, 2024

Ann Moyer, M.D., Ph.D., explains how Mayo Clinic Laboratories' unique genetic tests identify patients at high risk of severe reactions to fluoropyrimidines — a type of chemotherapy drug. Test results can guide clinical decision-making for safer cancer treatment.

View MoreView Less